Critical Contrast: International Isotopes (INIS) and Its Rivals

International Isotopes (OTCMKTS: INIS) is one of 26 public companies in the “Process control instruments” industry, but how does it weigh in compared to its peers? We will compare International Isotopes to similar companies based on the strength of its dividends, earnings, analyst recommendations, risk, profitability, institutional ownership and valuation.

Profitability

This table compares International Isotopes and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
International Isotopes 12.48% 42.90% 7.22%
International Isotopes Competitors -2.74% 6.28% 3.30%

Risk & Volatility

International Isotopes has a beta of -0.5, suggesting that its stock price is 150% less volatile than the S&P 500. Comparatively, International Isotopes’ peers have a beta of 0.73, suggesting that their average stock price is 27% less volatile than the S&P 500.

Earnings and Valuation

This table compares International Isotopes and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
International Isotopes $9.36 million $2.20 million 8.40
International Isotopes Competitors $2.34 billion $399.72 million 39.60

International Isotopes’ peers have higher revenue and earnings than International Isotopes. International Isotopes is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current recommendations for International Isotopes and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
International Isotopes 0 0 0 0 N/A
International Isotopes Competitors 123 718 1437 27 2.59

As a group, “Process control instruments” companies have a potential upside of 7.71%. Given International Isotopes’ peers higher possible upside, analysts plainly believe International Isotopes has less favorable growth aspects than its peers.

Insider & Institutional Ownership

66.3% of shares of all “Process control instruments” companies are owned by institutional investors. 13.1% of International Isotopes shares are owned by insiders. Comparatively, 9.4% of shares of all “Process control instruments” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

International Isotopes peers beat International Isotopes on 6 of the 10 factors compared.

About International Isotopes

International Isotopes, Inc. engages in the manufacture of nuclear medicine calibration and reference standards cobalt tele therapy sources, as well as radioisotopes and radiochemical for medical research and clinical devices. It operates through the following segments: Radiochemical Products, Cobalt Products, Nuclear Medicine Standards, Radiological Services. The Radiochemical Products segment includes production and distribution of various isotopically pure radio chemicals for medical, industrial, or research applications. The Cobalt Products segment includes management of a cobalt irradiation contract, fabrication of cobalt capsules for tele therapy or irradiation devices, and recycling of expended cobalt sources. The Nuclear Medicine Standards segment consists of the manufacture of sources and standards associated with Single Photon Emission Computed Tomography imaging, patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy industry. The Radiological Services Segment concerns a wide array of miscellaneous services that consists of gemstone processing and field services that include source installation, removal, and radia

Receive News & Ratings for International Isotopes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Isotopes and related companies with MarketBeat.com's FREE daily email newsletter.